Objective, peer-reviewed reporting on therapeutic peptides, regulatory updates, clinical trial results, and scientific consensus. No hype. No product sales.
Articles tagged Compounding Pharmacies.
The FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides for the 503A Bulks List. Here is a detailed breakdown of stakeholder reactions and the next steps in the regulatory process.
Day 2 of the FDA PCAC meeting produced mixed results: Epitalon passed 7-4, Semax passed 8-5, and Emideltide was the only peptide voted down across both days, failing 6-7. Here is the full breakdown.
The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on Day 1 to recommend BPC-157, KPV, and TB-500 for the 503A Bulks List, with MOTS-c passing 7-5. Here is a full breakdown of what happened, what was voted on, and what it means.
No articles match that search.